OHSU professor recognized with AAAS Martin and the Research Prize for Cancer Wachtel Rose -
American Association for the Advancement of Science recognizes Jeffrey Tyner, Ph.D., to accelerate the discovery of mutations -causing cancer and the development of targeted genetic treatments
Jeffrey Tyner, Ph.D., assistant professor of Cell & Developmental cancer Biology at Oregon Health & science University (OHSU) and a researcher with the OHSU Knight cancer Institute, has won a prestigious award from the American Association for the advancement of science (AAAS) for the development of a research program that identifies faster driving mutations of cancer of a patient and to accelerate the development of precision treatments. Tyner share price AAAS Martin and Rose Wachtel Cancer Research, which honors early-career cancer researchers, Li Ma, Ph.D., of the MD Anderson Cancer Center at the University of Texas.
Tyner price and entry My essays were published in the July edition of Science Translational Medicine 2. Both will be public lectures on their research July 7.
Tyner's work is distinguished by analyzing data on genetic mutations in cancer cells from patients, from deep genome sequencing, and at the same time to evaluate how tumor cells with these mutations respond to a variety of targeted genetic medicines. This approach determines specifically which are the most fatal aberrations and how they can be targeted with precision processing. It also allows a better understanding of the biology of the disease of each patient and, in some cases, identified new subtypes of the disease.
"complete delivery of the promise of genetic medicine leads will require that we make the jump from the knowledge of genetic events cancer and translate that information into new and personalized treatment regimens for patients," Tyner wrote in his essay prices.
studies reviewed by peers Tyner in Cancer Cell in 2012 and the New England Journal of Medicine last year demonstrate the benefits of this research approach. this latest study highlighted a case of two types of leukemia and has shown the possibility that these diseases could be treated with drugs approved by the existing FDA. accordingly, a clinical trial to test ruxolitinib in patients with chronic neutrophilic leukemia (CNL) which is driven by mutations in a gene called colony 3 receptor stimulating factor (CSF3R) is opening soon.
"Jeffrey Tyner work makes a significant contribution to the advancement of personalized medicine in oncology . His approach allows for new discoveries in the months that used to take decades, "said Brian Druker, MD, director of the Knight Cancer Institute. "It is gratifying to see his contributions recognized with AAAS and Martin Price Rose Wachtel cancer research."
The methodology of Tyner also form the backbone of Beat AML, a pioneering collaboration launched in 2013 between the leukemia & Lymphoma Society (LLS) and the Institute of cancer Chevalier to dramatically accelerate the development of treatments for patients with acute myeloid leukemia (AML). AML is a particularly devastating blood cancer with less than 25 percent of newly diagnosed patients surviving beyond five years. It causes more than 10,000 deaths annually in the United States, and treatment options has not changed much over the last 30 years.
Beat AML creates a profile of possible genetic drivers of AML by performing a deep genome sequencing analysis of samples of participants AML patients. for information from the samples is analyzed by the bioinformatics team at the Knight cancer Institute to identify potentially relevant mutations, the researchers simultaneously test the response of leukemia cells of patients to different drugs and drug combinations. This dual process on samples of patients better scientific team to confirm that they have correctly identified a genetic driver of the disease. It not only accelerates progress in the understanding of the AML, but more effectively identify ways to stop the disease and block potential recurrence.
Tyner said his laboratory will likely deploy a similar model for the development of drugs for other types of cancer in the future. "It is an honor to have this work recognized by the American Association for the Advancement of Science, and is another strong incentive to conduct research that will improve treatment options and clinical outcomes for patients. "
EmoticonEmoticon